The human Pena/Penb alloantigen system represents a naturally occurring polymorphism of human platelet membrane glycoprotein (GP) MIla, and has previously been implicated in the onset of two important clinical syndromes, neonatal alloimmune thrombocytopenic purpura and posttransfusion purpura. To investigate the molecular basis of the polymorphism underlying the Pen alloantigen system, we used the polymerase chain reaction to amplify platelet-derived GPIIIa mRNA transcripts. DNA sequence analysis of amplified GPIIIa cDNAs from nucleotides 161 to 1341 (encompassing amino acid residues 22-414) revealed a G526 -
Introduction
The human platelet membrane glycoprotein (GP)' IIb-IIIa complex is a member of the integrin family that is involved in adhesive interactions. In stimulated platelets, GPIIb-IIIa mediates platelet aggregation by serving as the receptor for fibrinogen and von Willebrand factor. The binding of these adhesive proteins to GPIIIa partly depends on their Arg-Gly-Asp (RGD) sequence which interacts with residues 109-171 of GPIIIa (1) .
In addition to its physiological role, both GPIIb and GPIIIa are known to bear a number of clinically important alloantigenic determinants that can induce an alloimmune response in two immunopathologic syndromes, posttransfusion purpura (PTP) and neonatal alloimmune thrombocytopenic purpura (NATP) (2) . To date, three different alloantigen systems have been localized to the GPIIb-IIIa complex, including P1A, Bak, and Pen. The molecular basis of the PjA and Bak system has been previously solved, an isoleucine to serine substitution at amino acid 843 of GPIIb that is responsible for Bak, and a leucine to proline dimorphism at amino acid 33 of GPIIIa for pjA (for a review, see reference 3).
The PlAkassociated polymorphism is most often implicated in causing NATP and PTP in the Caucasian population. However, the Pen alloantigen system is a more frequent cause of both of these alloimmune diseases in Asian individuals. In 1985, Friedman and Aster (4) reported the first description of the Pen alloantigen system in two cases of NATP, and showed that it was likely to be localized to either GPIIb or GPIIIa. Subsequently, Shibata et al. (5) reported an alloantigen system, designated Yuk, responsible for two cases ofNATP in Japan. A case of PTP associated with the Pen alloantigen system was later reported by Simon et al. (6) . The localization of the Yuk and Pen alloantigens to GPIIIa was demonstrated by Shibata et al. (7) and by Furihata et al. (8) , respectively, and together with serological data, it has been widely supposed that these two alloantigen systems may be identical.
Anti-Pen' alloantibodies completely inhibit ADP-induced platelet aggregation (8) , suggesting that the region of GPIIIa containing the Pen epitope may lie within a functionally important region ofthis membrane glycoprotein complex. Analysis ofproteolytic fragments ofGPIIIa have shown that the Pen' determinant is lost from GPIIIa coincident with the removal of a 30-kDa fragment ofGPIIIa by chymotrypsin (9) . Subsequent studies performed by Niewiarowski et al. (10) and Beer and Coller ( 11) have demonstrated the presence ofa large disulfidebonded loop in GPIIIa that is cleaved by chymotrypsin at residues 121 and 348. This region likely comprises the 30-kDa fragment removed from GPIIIa by chymotrypsin. Taken together, we have previously hypothesized that the Pen epitopes may be localized to the region bounded by GPIIIa residues 121-348 (3) . In this report, we provide evidence that an amino acid polymorphism within the RGD binding domain ofGPIIIa is responsible for the expression of the Pena/Penb alloantigen system.
Methods
Amplification ofplatelet mRNA. Platelet mRNA was prepared from whole blood of individuals of known Pen serological phenotypes according to methods described previously (12, 13) . Two sets of primers were designed to amplify the region ofGPIIIa mRNA from bases 161-1341 (encoding amino acid residues 22-414). The first set of primers consisted ofa forward primer 161-183 (5'-CATGTGTGCCTGGTGC-TCTGATG-31 and a reverse primer 698-674 (5'-CACCTGGTCAGT-TAGCGTCAGCACG-3), while the second primer pair was made up ofa forward primer from bases 633-658 (5'-GATATGAAGACCACC-TGCTTGCCCAT-3) and a reverse primer from nucleotides 1341-1315 (5'-TAAAGGACTTCTCCTTCTCCTGGGGAC-3'). PCR amplification was carried out in a DNA Programmable Thermal Controller (MJ Research, Inc., Watertown, MA) programmed to denature at 940C for 1.5 min, anneal at 500C for 1.5 min, and chain extend at 720C for 3 min. The reaction was allowed to proceed for 30 cycles followed by a final chain extension at 720C for 7 min to allow completion of strand synthesis. In some cases, two 25-bp primers flanking exon IIL(nucleotides 13622 to 14134) of the GPIIIa gene were used to amplify this region from genomic DNA that was isolated from peripheral whole blood.
Analysis ofPCR products. The resulting PCR products were subcloned into plasmid vector pGEM-5Zf (Promega Corp., Madison, WI) and the inserts sequenced by the dideoxy chain termination method using Sequenase T7 DNA polymerase (US Biochemical Corp., Cleveland, OH). In addition, PCR products were directly sequenced using the modified method of Bachmann et al. (14) . Briefly, glass-milk purified PCR products (Bio 101, Inc., La Jolla, CA) were resuspended in 5x Sequenase buffer, 16-20 pmol of sequencing primer, and 0.4 ,u 10% Nonidet P40 in a final vol of 10 gl. DNA was denatured by boiling for 5 min, followed by immediate cooling in a dry ice bath. Sequencing reactions were performed by using diluted dGTP labeling mix in a 5-min labeling reaction at room temperature followed by a 1-min chain termination reaction at 45°C. Amplified PCR products from both genomic DNA and cDNAs were also subjected to allele-specific hybridization analysis using two 13-base allele-specific oligonucleotide probes (13) . Probe A (5'-AGATGCGAAAGCT-3') corresponds to the published sequence of GPIIIa520 532, while probe B is nearly identical (5'-AGATGCAAAAGCT-3) differing only in the middle base that distinguishes the Pen' versus Penb alleles of GPIIIa (see Results).
Peptide competition and direct binding assays. Two 7-amino acid peptides encompassing amino acid 143 ofGPIIIa, TQMRKLT specific for Pen' and TQMQKLT specific for Penb, were synthesized at the Blood Research Institute Peptide Synthesis Core Facility. For the competition assay, 0.5 ug/well of the anti-GPIIIa monoclonal antibody, AP3, was plated overnight at 4°C in microtiter wells, and used to capture GPIIIa from Triton X-100 detergent lysates prepared from the platelets of a serologically defined Pen/"" individual. Preliminary studies using different dilutions of anti-Pena and anti-Penb alloantisera established that a 1:12 dilution gave 80-90% maximal binding to the AP3-captured GPIIIa. Therefore, this dilution was used in all future studies. 50 ul of either anti-Pena or anti-Penb alloantisera, diluted 1: 12, was preincubated in the presence or absence of these two peptides at concentrations ranging from 0.05 to 5.0 mM at room temperature for 1 h, and then added to the wells containing immobilized GPIIIa. After a 1-h incubation at room temperature, the binding of alloantibodies to the GPIIIa was detected using biotinylated HB43 (mouse anti-human IgG antibody) and avidin/biotinylated alkaline phosphatase complex (ABC reagent; Vector Laboratories, Inc. Burlingame, CA), according to manufacturer's directions. Bound HB43 was quantitated by measuring the OD at wavelength of 405 nm in an ELISA reader.
For the direct binding assay, 0.05-0.2 ,g of these two peptides dissolved in 100 ,g of carbonate buffer (pH 9.6) were plated directly in microtiter wells according to the method described by Flug et al. (15) . After blocking unbound sites with PBS containing 0.05% Tween 20 and 1% gelatin, alloantibodies (50 Ml of a 1:12 dilution of serum) were added to the wells and their binding was detected using biotinylated HB43 as described above. Several different peptides to which we had available specific anti-peptide antibodies were also plated under identical conditions and used as positive controls. Each ofthese control reactions yielded ODs of> 1.0 (not shown).
Construction ofallele-specific recombinantforms ofGPIIIa. Allelespecific recombinant forms ofGPIIIa were produced using a full length GPIIIa cDNA (Arg,43 form), the internal EcoRI restriction site of which had been removed by site-directed mutagenesis (kindly provided by Dr. Gilbert C. White II, The University of North Carolina, Chapel Hill, NC). A 261-bp fragment encompassing polymorphic base 526 was produced by digestion of amplified platelet cDNA derived from a Pen"'" individual using Xmn I and Bbv II. This fragment was then shuttled into the Bluescript vector containing GPIIIa/Arg,43 cDNA which had been digested with the same enzymes. Substitution ofA for G at base 526, as well asjunctional sequences that had been modified to produce recombinant GPIIIa isoforms, were confirmed by nucleotide sequence analysis. Finally, both the Arg,43 and Gln,43 cDNA constructs were subcloned into the EcoRI cloning site of the mammalian expression vector EMC-3 (generously provided by Dr. Glenn Larsen, Genetics Institute, Cambridge, MA). Plasmids used for subsequent transfection studies were purified by banding twice through CsCl gradients.
Expression and analysis of recombinant GPIIIa. Transfection of COS-7 cells with allele-specific recombinant forms of GPIIIa was performed using the DEAE-dextran method as described previously (16). Proteins synthesized by the transfected COS cells were metabolically labeled with [35S]methionine overnight. 1251 surfaced-labeled Triton X-100 platelet extracts derived from PI'A/A1 and Pen"/' individual were used as positive controls. Recombinant GPIIIa molecules synthesized by COS cells were immunoprecipitated using a monoclonal antiGPIIIa antibody, AP3 (not shown), as well as anti-Pena, anti-Pen", and anti-PI^' human alloantisera. The samples were analyzed on 7%-9% SDS-PAGE gel under reducing conditions. Platelet and COS cell lysates. The Triton-treated platelet lysates were prepared as described previously in the presence of EDTA and used in the ELISA (8) . '25I-surface-labeled platelets were lysed in a buffer containing 20 mM Tris, pH 7.4, 100 mM NaCl, 1% Triton X-100, 10 mM N-ethyleneimide, 2 mM phenylmethylsulfonyl fluoride. (PMSF), and 100 ,ug/ml leupeptin. COS cells were lysed in 50 mM Tris, pH 7.4, 150 mM NaCI, 1% Triton X-100, and 2 mM PMSF.
Results
Amplification and analysis ofnucleotides 161-1341 ofGPIIIa. Based upon our prediction that the region between residues 121 and 348 of GPIIIa might carry the Pen epitopes, we used two sets of primers to amplify platelet GPIIIa cDNA from nucleotides 161-1341 (encoding amino acid 22-414). The first 537 nucleotides in this region was PCR-amplified from platelet mRNA of known Pen phenotypes using primers that bounded bases 161-698, and as predicated, the major band obtained was 537 bp long (Fig. 1) 526 of GPIIIa (Fig. 2) . A second set of primers were used to amplify a 708-bp fragment bounded by nucleotides 633-1341, but no further nucleotide differences between Pen8 and Penb individuals were observed (data not shown).
To examine whether the polymorphism at base 526 segregated with the phenotypes of known serologically determined individuals, we performed direct PCR sequencing as well as allele-specific oligonucleotide hybridization (ASOH) analysis using 13 base oligonucleotide probes that differed only in the central nucleotide (13) . PCR amplification products used in these experiments were derived from both amplified genomic DNA constructed allele-specific recombinant forms of GPIIIa that differed only at residue 143, and analyzed them in a mammalian cell transfection system. Whereas anti-PlA' alloantibodies bound equally well to either the ArgI43 or GlnI43 isoforms ofthe GPIIIa molecule, anti-Pena antisera reacted with only the Arg,43 allelic form (Fig. 6 A) , while anti-Pen' immunoprecipitated only the GlnI43 form (Fig. 6 B) . These results demonstrate that amino acid 143 directly controls the expression of the Pen epitopes, and that the observed dimorphism is not limited to a simple genetic association.
Discussion
The purpose of the present study was to characterize, at a molecular biological and biochemical level, polymorphisms ofhuman platelet GPIIIa that might be responsible for the immunogenicity ofthe previously described Pens/Pen" platelet alloantigen system. Although the Penb phenotype is rare in the Caucasian population, its frequency among Asian individuals is 5-10-fold higher, and appears to be responsible for a majority ofthe PTP and NATP cases seen in Japan. We used a combination of platelet RNA PCR techniques, nucleotide sequencing, ASOH, synthetic peptide inhibition analysis, and mammalian transfection techniques to elucidate the molecular etiology of this clinically important platelet immunological disorder. Nucleotide sequence analysis of GPIIIa mRNA transcripts derived from the platelets of Pena/a and Penb"1 individuals re- vealed a single nucleotide substitution at base 526. Subsequent analysis ofPCR-amplified genomic DNA using a combination of direct nucleotide sequencing and ASOH analysis demonstrated that this nucleotide substitution segregated perfectly with the serologically determined phenotype of a number of Pena/a, Pena/b, and Pen"1" individuals. The molecular basis for this platelet membrane glycoprotein polymorphism, therefore, is similar to the previously solved plA and Bak alloantigen systems in that it represents a naturally occurring, genetically inherited allelic variant of the GPIIIa molecule, rather than a postsynthetically acquired antigenic determinant. ). The present work conclusively demonstrates the identity of these alloantigens at the molecular genetic level. In summary, we have identified a single Arg/Gln amino acid dimorphism at position 143 of GPIIIa that is responsible for the formation ofthe Pen' and Pen' human platelet alloantigens. Further localization ofthe Pen alloantibody binding sites on the GPIIIa molecule using chimeric integrin constructs in combination with recombinant GPIIIa fragments will likely provide additional clues as to the detailed structure of the Pen alloantigenic determinants. Our elucidation of the molecular genetic basis of the Pen' and Pen" allelic forms of the GPIIIa gene can now be exploited for the development of both preand post-natal diagnostic DNA typing for Pen phenotype, as has recently been demonstrated for the PlAl/PlI2 alloantigen system (20) .
